Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy.
Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy.
复制标题
DOI：
10.1007/s00330-021-08058-7
复制
发表时间：
2021-12
影响因子：
5.9
通讯作者：
Georgiades C
中科院分区：
文献类型：
--
作者：
Ghani MA;Fereydooni A;Chen E;Letzen B;Laage-Gaupp F;Nezami N;Deng Y;Gan G;Thakur V;Lin M;Papademetris X;Schernthaner RE;Huber S;Chapiro J;Hong K;Georgiades C
确定MRI三维全肝和基线肿瘤增强特征是否可以作为分期生物标志物，并比一维和非增强特征更准确地预测结直肠癌肝转移（CRCLM）患者的生存。本回顾性研究纳入了2001年至2014年间接受经动脉化疗栓塞或Y90经动脉放射栓塞治疗的88例CRCLM患者。在治疗前的MRI上对多达三个优势病变进行半自动分割，以计算总肿瘤体积（TTV）和总肝脏体积（TLV）。通过定量三维分析计算增强肿瘤体积（ETV）、增强肿瘤负荷（ETB，计算为ETV/TLV）、增强肝脏体积（ELV）、增强肝脏负荷（ELB，计算为ELV/TLV）。同时测量肿瘤的总直径和增强直径。采用改进的Kaplan-Meier方法确定每个指标的适当截止值。采用Kaplan-Meier生存曲线、单变量和多变量cox比例风险模型评估各参数的预测价值。除了全肝（ELB， ELV）和基于一维/非增强的方法外，所有方法都是独立的生存预测指标。多变量分析显示，增大肿瘤直径的风险比为2.1 (95% CI 1.3-3.4, p = 0.004)， TTV的风险比为1.7 (95% CI 1.1-2.8, p = 0.04)， ETV的风险比为2.3 (95% CI 1.4-3.9, p < 0.001)， ETB的风险比为2.4 （95% CI 1.4-4.0, p = 0.001）。CRCLM在基线MRI上的肿瘤增强与动脉内治疗后患者的生存密切相关，提示肿瘤体积增强和肿瘤负荷增强是比非增强和一维的标志物更好的预后指标。
To determine if three-dimensional whole liver and baseline tumor enhancement features on MRI can serve as staging biomarkers and help predict survival of patients with colorectal cancer liver metastases (CRCLM) more accurately than one-dimensional and non-enhancement-based features. This retrospective study included 88 patients with CRCLM, treated with transarterial chemoembolization or Y90 transarterial radioembolization between 2001 and 2014. Semi-automated segmentations of up to three dominant lesions were performed on pre-treatment MRI to calculate total tumor volume (TTV) and total liver volumes (TLV). Quantitative 3D analysis was performed to calculate enhancing tumor volume (ETV), enhancing tumor burden (ETB, calculated as ETV/TLV), enhancing liver volume (ELV), and enhancing liver burden (ELB, calculated as ELV/TLV). Overall and enhancing tumor diameters were also measured. A modified Kaplan-Meier method was used to determine appropriate cutoff values for each metric. The predictive value of each parameter was assessed by Kaplan-Meier survival curves and univariable and multivariable cox proportional hazard models. All methods except whole liver (ELB, ELV) and one-dimensional/non-enhancement-based methods were independent predictors of survival. Multivariable analysis showed a HR of 2.1 (95% CI 1.3–3.4, p = 0.004) for enhancing tumor diameter, HR 1.7 (95% CI 1.1–2.8, p = 0.04) for TTV, HR 2.3 (95% CI 1.4–3.9, p < 0.001) for ETV, and HR 2.4 (95% CI 1.4–4.0, p = 0.001) for ETB. Tumor enhancement of CRCLM on baseline MRI is strongly associated with patient survival after intra-arterial therapy, suggesting that enhancing tumor volume and enhancing tumor burden are better prognostic indicators than non-enhancement-based and one-dimensional-based markers.
登录
查看更多内容
影响因子：
4.8
作者：
Tacher, Vania;Lin, MingDe;Geschwind, Jean-Francois
通讯作者：
Geschwind, Jean-Francois
影响因子：
4.8
作者：
Pellerin, Olivier;Lin, MingDe;Geschwind, Jean-Francois
通讯作者：
Geschwind, Jean-Francois
影响因子：
19.7
作者：
Sahu S;Schernthaner R;Ardon R;Chapiro J;Zhao Y;Sohn JH;Fleckenstein F;Lin M;Geschwind JF;Duran R
通讯作者：
Duran R
DOI：
10.1111/j.1463-1318.2011.02765.x
发表时间：
2012-02
期刊：
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
影响因子：
--
作者：
Edwards MS;Chadda SD;Zhao Z;Barber BL;Sykes DP
通讯作者：
Sykes DP
影响因子：
45.3
作者：
Hendlisz, Alain;Van den Eynde, Marc;Flamen, Patrick
通讯作者：
Flamen, Patrick